Aptinyx: Q2 Earnings Insights
Aptinyx (NASDAQ:APTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Aptinyx beat estimated earnings by 7.14%, reporting an EPS of $-0.26 versus an estimate of $-0.28.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
This Healthcare Stock Jumps Around 188%, Here’s 83 Biggest Movers From Yesterday
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows.
Piper Sandler Maintains Overweight on Aptinyx, Lowers Price Target to $6
Piper Sandler analyst Christopher Raymond maintains Aptinyx (NASDAQ:APTX) with a Overweight and lowers the price target from $10 to $6.
Aptinyx To Present Preclinical Data On NYX-783 In Models Of PTSD At 2022 Society Of Biological Psychiatry Annual Meeting
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented data from preclinical studies of NYX-783
Expert Ratings for Aptinyx
Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings: